E BioSig: An Emerging Medical Device Developer Making Strides In Catheter-Based Electrophysiology

TM editors' note: This article discusses a penny stock and/or microcap. Such stocks are easily manipulated; do your own careful due diligence.

Today I am discussing an emerging medical device developer called BioSig Technologies (BSGM). This company operates within the medical device subindustry, has roughly an $21 million market cap and is listed on the OTC. One of the reasons why this company is an interesting investment opportunity is that it is targeting a large indication in catheter-based electrophysiology (EP). Specifically, BioSig is attempting to complement existing recording systems situated in an electrophysiology lab with its PURE EP system. According to BioSig CEO Gregory Cash, the technology "provides a multitude of essential information in real-time; information that is not obtainable with any other equipment presently in the EP lab." This represents a multi-billion dollar opportunity for BioSig.

There are very few companies that offer real exposure to the EP market. According to my research, BioSig is one such company that is immersed in the development of medical devices targeting this indication. Thus, should the company advance a product to market (which is expected as early as 2016), investors could be provided an opportunity for growth that is not possible in some of the more prominent medical device companies. It is important to note, however, that investing in such a company comes with the inherent risks of shareholder dilution, clinical failure, and intense market competition. Thus, it is at the discretion of you, the reader, to approach BioSig given the significant risks that accompany any investment in the equity.

Given the lack of coverage of BioSig, I felt compelled to further investigate the company's various developments. I reached out for an interview with Gregory Cash, President, CEO, and Director of BioSig. Please read CEO Cash's bio on the company website, available here. Following is my interview with Mr. Cash.

Could you summarize BSGM’s pipeline?

BSGM’s PURE EP™ System is a next-generation multichannel surface electrocardiogram and intracardiac electrophysiology (EP) recording platform. It is designed to allow for precise, uninterrupted, real-time evaluations of electrocardiograms and electrograms during electrophysiology procedures ranging from simple diagnostic tests to catheter ablation for the most complex cases of arrhythmias.

PURE EP is being developed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings and providing guidance in identifying ablation targets. Based on needs in the field, we expect to continue innovating improved and novel technologies.

 How is BSGM positioned for future revenue growth?

BSGM expects to begin generating revenue in the second half of 2016 with its first generation of the PURE EP System. Additional software upgrades/features would allow for additional revenue growth.

In addition, BSGM’s management is constantly evaluating different avenues to add a disposable component – a key growth factor.

How do you perceive your competitors in the indications BSGM is targeting?

The technology in the PURE EP System is positioned to complement, rather than compete with, the existing recording systems situated in an electrophysiology lab. BSGM believes that PURE EP provides a multitude of essential information in real-time; information that is not obtainable with any other equipment presently in the EP lab.    

1 2 3 4
View single page >> |

Disclosure: The information presented is for entertainment purposes only, and in no way should it be construed as investment advice. I am not receiving any compensation for the said article ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.